Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12133623 | 0.89 | KMT2A (0.76) | HDAC1HDAC6KMT2AMEN1ALDH1A1 | |
| SCHEMBL1501994 | 0.83 | KMT2A (0.63) | HDAC1HDAC6KMT2AALDH1A1POLB | |
| SCHEMBL24575914 | 0.83 | TGM2 (0.63) | KMT2ATGM2MEN1ALDH1A1L3MBTL1 | |
| SCHEMBL171709 | 0.81 | KMT2A (0.66) | HDAC1HDAC6KMT2AMEN1ALDH1A1 | |
| SCHEMBL3612557 | 0.81 | KMT2A (0.66) | HDAC1HDAC6KMT2AMEN1ALDH1A1 | |
| SCHEMBL885068 | 0.81 | KMT2A (0.66) | HDAC1HDAC6KMT2AALDH1A1POLB | |
| SCHEMBL1694370 | 0.81 | L3MBTL1 (0.62) | KMT2ATGM2MEN1ALDH1A1POLB | |
| SCHEMBL3612554 | 0.81 | KMT2A (0.66) | HDAC1HDAC6KMT2AALDH1A1POLB | |
| SCHEMBL1951513 | 0.81 | KMT2A (0.66) | HDAC1HDAC6KMT2AALDH1A1POLB | |
| SCHEMBL15947376 | 0.81 | KMT2A (0.66) | HDAC1HDAC6KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187613-B9 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-10-25 | — | — | EP | claimed |
| EP-1187613-B1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-09 | — | — | EP | claimed |
| CN-122036718-A | ALK5 inhibitor and preparation method and application thereof | 安炎达医药技术(广州)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| CN-115836054-B | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| CN-115836054-A | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4146644-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2008128711-A1 | INSECTICIDAL ARYL PYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| EP-1778639-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006094800-A2 | CASCADE REACTION PROCESS | SYNTHON B.V. (NL) | 2006-09-14 | — | — | WO | disclosed |
| US-20060063766-A1 | Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | CURIA GLOBAL, INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2004085420-A1 | BICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2004-10-07 | — | — | WO | disclosed |
| US-5039673-A | Anticoagulants, bronchodilators, vasodilators | GLAXO GROUP LIMITED (GB) | 1991-08-13 | — | — | US | disclosed |
| EP-0296802-A1 | Aminocyclopentyl ethers and their preparation and pharmaceutical formulation | GLAXO GROUP LIMITED (GB) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063766-A1 | Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin | SLC6A3, SLC6A4, SLC6A2 | HDAC1 1846/4885HDAC6 2310/4885KMT2A 1904/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | HDAC1 10/4885HDAC6 123/4885KMT2A 373/4885 |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | OPRK1, OPRL1, OPRD1 | HDAC1 104/4885HDAC6 303/4885KMT2A 206/4885 |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | HDAC1 2995/4885HDAC6 1362/4885KMT2A 1230/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | HDAC1 10/4885HDAC6 123/4885KMT2A 373/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | HDAC1 4555/4885HDAC6 2636/4885KMT2A 3083/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | HDAC1 188/4885HDAC6 380/4885KMT2A 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.